Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ciphergen Biosystems(CIPH): -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (86)	12/9/2002 4:19:23 PM
From: nigel bates	Respond to of 510

FREMONT, Calif., Dec. 9 /PRNewswire-FirstCall/ -- Ciphergen Biosystems KK, a joint venture of Ciphergen Biosystems, Inc. (Nasdaq: CIPH - News) and SC BioSciences, a subsidiary of Sumitomo Corporation, announced today the opening of a Biomarker Discovery Center® to serve the clinical proteomics needs of its customers in Japan. Modeled after successful centers established beginning in 2000 by Ciphergen Biosystems in California, Pennsylvania and Denmark, the Biomarker Discovery Center in Japan will provide accelerated biomarker discovery and validation services in pharmaceutical drug discovery, pharmacology, toxicology and clinical trials studies. The Japan Biomarker Discovery Center is equipped with multiple ProteinChip® Biomarker Systems, Biomek robotics to enhance throughput and reproducibility, and a Tandem Mass Spectrometer outfitted with a ProteinChip Interface. This center will enjoy first access to next generation products that are being developed by Ciphergen. Most importantly, the Biomarker Discovery Center will be staffed by PhD and M.D. level scientists who are experts in the use of the SELDI ProteinChip System for protein biomarker discovery and clinical trials using differential protein expression and pattern recognition analysis, protein characterization and identification, protein interaction studies and assay development. The Japan Biomarker Discovery Center is located at Ciphergen Biosystems KK's recently expanded laboratory facilities in Yokohama. William E. Rich, Ciphergen's CEO commented, "We have found in the United States and in Europe that our customers truly benefit from a local biomarker center with the ability to discover new biomarkers, run validation studies rapidly on their behalf, and then have the flexibility to transfer the technology in-house through ProteinChip System purchases to enable their own on-site programs." Toru Umehara, President of Ciphergen Biosystems KK, added, "We are pleased to now be providing Biomarker Discovery Center collaborative services to meet the needs of our growing customer base in Japan. This allows us to provide a complete solution to the protein research needs of our pharmaceutical and academic customers."

To: tuck who wrote (86)	12/9/2002 4:23:56 PM
From: tuck	Read Replies (1) \| Respond to of 510

This is an interesting move given that litigation in this area is on tap pretty soon. Although a) it was probably planned some time ago, and b) if Igen is any example, resolution of the litigation is likely not that close. I don't know what the odds of pre-trial settlement might be. My impression of Hutchens is that his attitude is similar to Igen's adversary, Roche, though Hutchens has a better case than Roche ever had against Igen. I continue to think his odds are a bit less than even. Cheers, Tuck